STOKE THERAPEUTICS INC(NASDAQ:STOK) stock News

STOK Latest News, Press Relases and Analysis

All

Press Releases

20 hours ago - By: Benzinga - Mentions: AHR MCS TER VRNT ...

This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

3 days ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9 days ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

a month ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9 days ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

2 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

4 months ago - By: Benzinga

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics

2 months ago - By: Zacks Investment Research

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

2 months ago - By: Zacks Investment Research - Mentions: BRTX

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

2 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Zacks Investment Research - Mentions: ALT HQY DOCS

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

3 months ago - By: Zacks Investment Research - Mentions: BIIB SAGE

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

3 months ago - By: Zacks Investment Research - Mentions: CGON

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

3 months ago - By: Investor's Business Daily - Mentions: BIIB

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar

3 months ago - By: Zacks Investment Research - Mentions: BPMC

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

3 months ago - By: Zacks Investment Research

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

4 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

4 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces CEO Transition

5 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

5 months ago - By: Bloomberg - Mentions: BIIB

Biogen Bets Up to $550 Million for Rights to Epilepsy Drug

5 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

5 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

6 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

6 months ago - By: Stoke Therapeutics

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

6 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

7 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

8 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

8 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

9 months ago - By: Stoke Therapeutics, Inc.

STOKE THERAPEUTICS INC (STOK) Stock News

STOK Latest News, Press Relases and Analysis

This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Stoke Therapeutics Announces CEO Transition

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Biogen Bets Up to $550 Million for Rights to Epilepsy Drug

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates